Breast Cancer. Malignant neoplasm of breast
Conditions
Interventions
Intervention 1: Intervention group: Nano-Comintern at a dose of 80 mg/day (Exir Nano Sina Co., Iran) is given orally form for 7 consecutive days before chemotherapy until 6 months later. Intervention
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with breast cancer who planned for antracycline-based chemotherapy
Exclusion criteria
Exclusion criteria: presence of cardiomyopathy (dilated, restrictive or hypertro-phic) detected by baseline echocardiography Past medical history of coronary heart disease Moderate or severe aortic and/or mitral valve disease Prior chemotherapy or radiotherapy, Alcohol abuse Any contraindications to Curcumin Patients on other cardiac medications such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, non-dihydropyridine calcium channel blockers, diuretics, statins or beta-blockers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular (LV) end-systolic and end-diastolic diameters (LVESD, LVEDD), systolic and diastolic function. Timepoint: Echocardiographic measurements including LVESD, LVEDD at baseline. and at 6-month after the start of chemoterapy. Method of measurement: Echocardiography measurements by a specialist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHassan Mehrad-Majd
Mashhad University of Medical Sciences
Outcome results
None listed